Clinical Trial Update: Efficacy and Safety of 3 Doses of HL10 Given at Fixed Time Intervals Compared to Standard Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating three fixed-interval doses of HL10 versus standard therapy in acute lung injury and acute respiratory distress syndrome was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• HL10

Snippet

Sponsor: LEO Pharma | Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome | Phase 3 | Status: TERMINATED